Anna, a Myriad Oncology patient, who has used MyRisk® Hereditary Cancer test

MYRISK® HEREDITARY CANCER TEST WITH RISKSCORE®

The complete solution for hereditary cancer risk assessment and care planning

The MyRisk Test evaluates 63 guideline-recommended genes associated with hereditary cancer risk–essential to identify whether patients with a personal or family history of certain cancers are at an increased risk of developing specific types of cancer and empowering healthcare providers to personalize care plans and prevention plans.

1 in 4 women without cancer qualify for germline genetic testing.1

Reveal hidden breast cancer risk. Personalize prevention—for every patient.

The MyRisk Test with RiskScore combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover what gene testing alone can’t, helping you to make more informed decisions in breast cancer risk assessment and management.

  • Evaluates 63 guideline-recommended genes associated with hereditary cancer risk—and excludes those without clinical relevance
  • Includes all 13 breast cancer susceptibility genes more strongly recommended* (BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, TP53) and less strongly recommended† (ATM, BARD1, CHEK2, RAD51C, RAD51D, NF1) by ASCO guidelines, as well as recommended Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM)2
  • Provides each unaffected patient meeting criteria with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer
  • Validated with outcomes data from >130,000 patients across all ancestries3-5

Choose the most comprehensive and inclusive breast cancer risk test3-5

Graphic showing different components that make up the MyRisk® with RiskScore assessment tool

More than a test, an ally in preventative care

Myriad helps you implement a Breast Cancer Risk Assessment program into your practice

  • Full rollout coordination, staff training, operational support​
  • Patient-first resources and patient education by our board-certified genetic counselors—at no extra cost

Get in touch

The MyRisk Test with RiskScore uncovers hidden risk so you can treat with confidence

  • The MyRisk Test with RiskScore offers improved risk stratification that is two times more predictive of breast cancer risk than Tyrer-Cuzick alone, empowering you and your patients to make informed, proactive decisions to help prevent cancer or detect it early, when treatment is most effective.3
  • Over half of patients who test negative for a hereditary cancer syndrome will have a change in medical management due to their family history of cancer and/or their RiskScore.6

Graph depicting a x2 increase in the predictive accuracy of breast cancer risk scores using MyRisk than Tyrer-Cuzick alone

Chart showing MyRisk definitively classifies up 63% of variants other labs may not

Accurate testing that goes beyond patients’ initial test results

Myriad is the industry leader in variant classification and reclassification. We use proprietary variant classification tools, including RNA testing and other cutting-edge technology, to provide comprehensive, clinically actionable and accurate results.

Reducing uncertainty for more patients

The MyRisk Test offers the industry’s lowest reported VUS rates for BRCA1 and BRCA2 of 0.3% and 0.7%, respectively.7

Lifetime Classification Commitment

Myriad continuously re-evaluates VUS and sends amended reports whenever a patient’s result is reclassified as clinically significant.

Make confident risk management decisions with definitive answers

Every MyRisk Test report includes:

  • Germline results with clinically significant mutations found as well as VUSs detected
  • Summary of clinical, personal, and family cancer history reported on test request form
  • Comprehensive assessment of a patient’s hereditary cancer risk
  • Personalized medical management recommendations in line with current guidelines
  • Information to help family members understand their potential genetic risk

How to order the MyRisk Test

Myriad offers several ordering options for the MyRisk Test to better serve your patients and your practice, including portals for online ordering and options for sending MyRisk test kits directly to your patients’ homes.

View ordering options

Workflow solutions from Myriad can optimize your hereditary cancer risk assessment program

Myriad offers simplified workflow solutions that are customizable to your practice, saving staff time and reducing administrative burden.

  • Resources and support to help implement a Breast Cancer Risk Assessment Program
  • Tools to help identify patients who meet germline testing guidelines to inform treatment decisions
  • Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor
  • Easy ordering options including paper, online, virtual, and EMR
  • Transparent pricing with personalized cost estimates, financial assistance, and other affordability options including direct pay
  • Results available on average 14 days from sample receipt
  • Comprehensive, clear, and easy-to-follow results so you can focus on patient treatment

Real expert support

First-class support from our team of board-certified genetic counselors gives you on-demand access to the information you need for every patient, every test, every time.

Workflows

Workflow solutions allow for simple integration of Myriad’s tests into routine clinical care and help patients better understand and benefit from their results. 

Play button

MyRisk Patient Story

Forging a path forward

Lisa’s mom’s battle with breast cancer inspired her to get genetic testing and make a life-saving choice. Her story is a testament to courage and resilience.

Watch video

Image showing Myriad's portfolio of germline and tumor genomic test kits

One simple order. Comprehensive results.

With Myriad, you can receive comprehensive results for germline testing, tumor genomic profiling, and companion diagnostic options in one single ordering experience, getting clear, fast answers for your patients.

What to expect with every MyRisk Test

Actionable

MyRisk Testing offers clinically actionable results and personalized management guidance to inform confident patient care.

View a sample report

Affordable

Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay.

Learn more

Accurate

The MyRisk Test delivers unmatched accuracy, with variant classification techniques independently verified and clinically validated at >99.9% accuracy.9

TAKE THE NEXT STEP WITH THE MYRISK TEST

Discover how we help clinics implement Breast Cancer Risk Assessment programs with full rollout coordination, staff training, operational support.

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

MyRisk resources

References:

  1. DeFrancesco MS, Waldman RN, Pearlstone MM, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstet Gynecol. 2018;132(5):1121-1129.
  2. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  3. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. Genet Med. 2024;26(7):101128.
  4. Hughes E, Wagner S, Pruss D, et al. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. JCO Precis Oncol. 2022;6:e2200084.
  5. Hughes E, Probst B, Pederson HJ, et al. A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCV8) and a polygenic risk score (PRS) for diverse ancestries. J Clin Oncol. 2022;40(16_suppl):557-557.
  6. Myriad internal data based on MyRisk tests reported between 09/01/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
  7. Mundt E, McGreevy K, Nix P, Cummings S. Myriad’s Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025.
  8. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  9. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next-generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
  10. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.

©2025 Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific. Eurobio Scientific has licensed the EndoPredict test to Myriad Genetics in select territories.

Locations

United States
Europe
Japan